Celldex Announces Upcoming Late Breaking Oral Presentation of 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria at ACAAI 2024

3 weeks ago

HAMPTON, N.J., Oct. 25, 2024 ( GLOBE NEWSWIRE ) -- Celldex Therapeutics, Inc. ( NASDAQ:CLDX ) announced today that 12 week results from the Company's Phase 2 clinical trial of barzolvolimab in two of the most common forms of chronic inducible urticaria ( CIndU ) -cold urticaria ( ColdU ) and ...

Ticker	Sentiment	Impact
CLDX	Neutral	6 %